Related Experiment Video
Updated: Sep 14, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
RSV vaccine uptake among seniors: A path analysis approach
Filip Viskupič1, David L Wiltse2, Gemechis Djira3
1Department of Political Science, Iowa State University, USA.
None:
In May 2023, the first respiratory syncytial virus (RSV) vaccines were approved for adults 60 years and older in the United States. In April 2024, we fielded a survey in the state of South Dakota to investigate RSV vaccine uptake among this vulnerable population group. The survey measured RSV vaccine uptake, uptake of other vaccines, and other social and political variables associated with vaccine uptake. We analyzed the data using path analysis in SAS statistical software. The sample consisted of 376 participants 60 years and older. Of those, 33 % received the RSV vaccine. Path analysis results showed direct associations between RSV vaccine uptake and COVID-19 vaccine uptake (standardized effect of 0.2548, p < 0.0001) and flu vaccine uptake (standardized effect of 0.1883, p = 0.0001), as well as indirect associations between partisan self-identification (standardized effect of -0.1354, p < 0.0001) and trust in government (standardized effect of 0.0969, p < 0.0001).
More Related Videos
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Statistical Methods for Analyzing Epidemiological Data
Principles of Disease Surveillance
Vaccinations
Bias in Epidemiological Studies
Relative Risk

